This summary was created by AI, based on 10 opinions in the last 12 months.
Vertex Pharmaceuticals Inc. (VRTX-Q) has garnered mixed reviews from experts following its performance and pipeline developments. The company has made significant strides with its non-addictive painkiller, leading to a 20% increase in shares this year, and its cystic fibrosis portfolio also continues to perform well. However, some analysts express caution due to disappointing updates concerning a key drug and concerns surrounding free cash flow entering 2024. Despite these challenges, the overall sentiment leans positive, with many experts believing in the long-term potential of Vertex's innovative treatments. The stock remains a strong consideration for investors focusing on its growth trajectory in pain management and other therapeutic areas.
Vertex Pharmaceuticals Inc. is a American stock, trading under the symbol VRTX-Q on the NASDAQ (VRTX). It is usually referred to as NASDAQ:VRTX or VRTX-Q
In the last year, 10 stock analysts published opinions about VRTX-Q. 6 analysts recommended to BUY the stock. 2 analysts recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for Vertex Pharmaceuticals Inc..
Vertex Pharmaceuticals Inc. was recommended as a Top Pick by on . Read the latest stock experts ratings for Vertex Pharmaceuticals Inc..
Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.
10 stock analysts on Stockchase covered Vertex Pharmaceuticals Inc. In the last year. It is a trending stock that is worth watching.
On 2025-04-01, Vertex Pharmaceuticals Inc. (VRTX-Q) stock closed at a price of $484.74.
A strong performer in this market, not pulling back. Everybody is excited over their pain drug, and other drugs in the pipeline as well.